Control of tumour vascular permeability

Advanced Drug Delivery Reviews

Volumn 34, Issue 1, 1998, Pages 109-119

  Baban, Dilair F ^a   Seymour, Leonard W ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Drug delivery; EPR effect; Macromolecules; Tumour targeting; Vascular permeability; Vascular structure; VPF VEGF

Indexed keywords

ANTIBODIES; BLOOD VESSELS; CELL MEMBRANES; DNA; GENES; MACROMOLECULES; MECHANICAL PERMEABILITY; ONCOLOGY;

GENE THERAPY; PATHOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF);

CONTROLLED DRUG DELIVERY;

ANTIBODY; ANTINEOPLASTIC AGENT; GROWTH FACTOR; IODINATED POPPYSEED OIL; NITRIC OXIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CANCER; CELL MEMBRANE; GENE TARGETING; GENE THERAPY; HUMAN; MACROMOLECULE; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0032487348     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00003-9     Document Type: Review

References (120)

1. Seymour L.W. Passive tumour targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;135-187.
2. Schackert G., Simmons R.D., Buzbee T.M., Hume D.A., Fidler I.J. Macrophage infiltration into experimental brain metastases: Occurrence through an intact blood-brain barrier. J. Natl. Cancer Inst. 80:1988;1027-1034.
3. Zhang R.D., Price J.E., Fujimaki T., Bucana C.D., Fidler I.J. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am. J. Pathol. 141:1992;1115-1124.
4. Joyner W.L., Kern D.F. Microvascular permeability to macromolecules and its dynamic modulation. Adv. Drug Deliv. Rev. 4:1990;319-334.
5. Folkman J. What is the evidence that tumours are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
6. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 267:1992;10931-10934.
7. Gimbone M., Leapman S., Cotran R., Folkman J. Tumour dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136:1972;261-276.
8. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:1989;58-60.
9. Blood C.H., Zetter B.R. Tumour interactions with the vasculature: Angiogenesis and tumour metastasis. Biochim. Biophys. Acta. 1032:1990;89-118.
10. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell. 64:1991;327-336.
11. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumour angiogenesis and metastasis: Correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1991;1-8.
12. Horak E.R., Leek R., Klenk N., Lejeune S., Smith K., Stuart N., Greenall M., Stepniewska K., Harris A.L. Angiogenesis, assessed by platelet endothelial cell adhesion molecule Ab, as indicator of node metastases and survival in breast cancer. Lancet. 340:1992;1120-1124.
13. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., Angeletti C.A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 340:1992;145-146.
14. Olivarez D., Ulbricht T., DeRiese W., Foster R., Reister T., Einhorn L., Sladge G. Neovascularisation in clinical stage A testicular germ cell tumour: Prediction of metastatic disease. Cancer Res. 54:1994;2800-2802.
15. Folkman J., Klagsbrun M. Angiogenic factors. Science. 235:1987;442-445.
16. Klagsbrun M., D'Amore P.A. Regulators of angiogenesis. Annu. Rev. Physiol. 53:1991;217-239.
17. Hobson B., Denekamp J. Endothelial proliferation in tumours and normal tissues: Continuous labelling studies. Br. J. Cancer. 49:1984;405-413.
18. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 9:1990;267-282.
19. Jain R.K. determinants of tumour blood flow: A review. Cancer Res. 48:1988;2641-2658.
20. Vaupel V., Kallinowski F., Okunieff P. Bloodflow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: A review. Cancer Res. 49:1989;6449-6465.
21. Jain R.K. Transport of molecules in the tumour interstitium. Cancer Res. 47:1987;3039-3051.
22. Roh H-D., Boucher Y., Kalnicki S., Buchsbaum R., Bloomer W.D., Jain R.K. Interstitial hypertension of uterine cervix in patient: Possible correlation with tumour oxygenation and radiation response. Cancer Res. 51:1991;6695-6698.
23. Boucher Y., Lee I., Jain R.K. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumours. Microvasc. Res. 50:1995;175-182.
24. Zanti C.A., Rosenstein M., Boucher Y., Epperly M.W., Jain R.K. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumour xenograft. Cancer Res. 56:1996;964-968.
25. Baish J.W., Gazit Y., Berk D.A., Nozue M., Baxter L.T., Jain R.K. Role of tumour vascular architecture in nutrient and drug delivery. An invasion percolation based network model. Microvasc. Res. 51:1996;327-346.
26. Gerlowski L.E., Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31:1986;288-305.
27. Jain R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumours. Cancer Metastasis Rev. 9:1990;253-266.
28. Yuan F., Leunig M., Berk D.A., Jain R.K. Microvascular permeability of albumin, vascular surface area and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc. Res. 45:1993;269-289.
29. Wu N.Z., Klitzman B., Rosner G., Needham D., Dewhirst M.W. Measurement of material extravasation in microvascular networking using fluorescence video microscopy. Microvasc. Res. 46:1993;231-253.
30. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human xenograft. Cancer Res. 54:1994;3352-3356.
31. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
32. Litzinger D.C., Buiting A.M.J., Vanrooijen N., Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta - Biomembranes. 1190:1994;99-107.
33. Gabizon A., Chemla M., Tzemach D., Horowitz A.T., Goren D. Liposome longevity and stability in circulation - effect on the in-vivo delivery to tumour and therapeutic efficacy of encapsulated anthracyclines. J. Drug Targeting. 3:1996;391-398.
34. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumour tissues. Cancer Res. 53:1993;3765-3770.
35. Babson A.L., Winnick T. Protein transfer in tumour-bearing rats. Cancer Res. 14:1954;606-608.
36. Hradec J. Metabolism of serum albumin in tumour-bearing rats. Br. J. Cancer. 12:1961;290-295.
37. 131I-labelled antibody which reacts with human fibrin. Preliminary tracer studies on tumour patients. Cancer Res. 24:1964;286-289.
38. H. Isliker, J.C. Cerottini, J.C. Jaton, G. Magnenat, Specific and Non-specific Fixation of Plasma Proteins in Tumours, Chemotherapy of Cancer, Elsevier, Amsterdam, 1969, pp. 278-295.
39. Peterson H.I., Appelgren K.L. Experimental studies on the uptake and retention of labelled protein in a rat tumour. Eur. J. Cancer. 9:1973;543-548.
40. Butler T.P., Grantham F.H., Gullino P.M. Bulk transfer of fluid in the interstitial compartment of mammary tumours. Cancer Res. 35:1975;3084-3088.
41. 97Ru-transferrin uptake in tumour and abcess. Eur. J. Nucl. Med. 8:1983;491-496.
42. Rogers W., Edlich R.F., Aust J.B. Tumour blood flow. II. Distribution of blood flow in experimental tumours. Angiology. 20:1969;374-387.
43. Tannock I.F., Steel G.G. Quantitative techniques for study of the anatomy and function of small blood vessels in tumours. J. Natl. Cancer Inst. 42:1969;771-782.
44. Hilmas D.E., Gillette E.L. Morphometric analyses of the microvasculature of tumours during growth and after x-irradiation. Cancer. 33:1974;103-110.
45. Papadimitrou J.M., Woods A.E. Structural and functional characteristics of the microcirculation in neoplasms. J. Pathol. 116:1975;65-72.
46. Lurie A.G., Tatematsu M., Nakatsuka T., Rippey R.M., Ito N. Anatomical and functional vascular changes in hamster cheek pouch during carcinogenesis induced by 7,12-dimethylbenzene(a)anthracene. Cancer Res. 43:1983;5986-5994.
47. Dvorak H.F., Harvey V.S., McDonagh J. Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinoma. Cancer Res. 44:1984;3348-3354.
48. Weiss L., Tveit E., Hultborn R. Vascular resistance characteristic of 7,12-dimethylbenz(a)anthracene induced rat mammary tumours and normal tissues as studied in vitro. Cancer Res. 45:1985;2478-2480.
49. Knierim M., Paweletz N., Finze E.M. Tumour-related reconstitutive vascularization. An ultrastructural study. Anticancer Res. 6:1986;1305-1315.
50. Brown L.F., Asch B., Harvey V.S., Buchinski B., Dvorak H.F. Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinoma. Cancer Res. 48:1988;1920-1925.
51. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumours that are leaky to circulating macromolecules. Am. J. Pathol. 133:1988;95-109.
52. Nagy J.A., Brown L.F., Senger D.R., Lanir N., Van De Water L., Dvorak A.M. Pathogenesis of tumour stroma generation: A critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta. 948:1988;305-326.
53. Dvorak H.F., Nagy J.A., Dvorak A.M. Structure of solid tumours and their vasculature: Implication for therapy with monoclonal antibodies. Cancer Cells. 3:1991;77-85.
54. Shockley T.R., Lin K., Nagy J.A., Tompkins R.G., Dvorak H.F., Yarmush M.L. Penetration of tumour tissue by antibodies and other immunoproteins. Ann. N.Y. Acad. Sci. 618:1991;367-382.
55. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer therapy: Mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 46:1986;6387-6392.
56. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Subr V., Strohalm J., Duncan R. Tumour tropism and anticancer efficacy of polymer-based anthracycline prodrug. Br. J. Cancer. 70:1994;636-641.
57. Seymour L.W., Shoaibi M.A., Soyez H., De Marre A., Schacht E.H. Improved anticancer efficacy and decreased toxicity of mitomycin C linked to a soluble synthetic polymer. Anti-Cancer Drug Des. 11:1996;351-365.
58. Konno T., Maeda H., Iwai K., Maki S., Tashiro S., Uchida M., Miyauchi Y. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumours by arterially administered lipid contrast medium. Cancer. 54:1984;2367-2374.
59. Kobayashi M., Maeda H., Imai K., Konno T., Sugihara S., Yamanaka H. Tumour-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma. Urology. 37:1991;288-294.
60. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6:1991;181-202.
61. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C., Harvey V.S., Dvorak H.F. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
62. 2-terminal amino acid sequence of guinea pig tumour secreted vascular permeability factor. Cancer Res. 50:1990;1774-1778.
63. Senger D.R., Perruzzi C.A., Feder J., Dvorak H.F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumour cell lines. Cancer Res. 46:1986;5629-5632.
64. Miles A.A., Miles E.M. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea pigs. J. Physiol. 118:1952;228-257.
65. Connolly D.T., Olander J.V., Heuvelman D., Nelson R., Monsell R., Siegel N., Haymore B.L., Leimgruber R., Feder J. Human vascular permeability factor. Isolation from U937 cells. J. Biol. Chem. 264:1989;20017-20024.
66. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
67. Leung D.W., Cachianes G., Kuang W., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
68. Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13:1992;18-32.
69. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 36:1995;127-137.
70. Kolch W., Martimy-Baron G., Kieser A., Marme D. Regulation of the expression of VEGF/VPF and its receptors: Role in tumour angiogenesis. Breast Cancer Res. Treat. 36:1995;139-155.
71. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5:1991;1806-1814.
72. Tischer E., Mitchell R., Hartman T., Silva M., Gospondarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266:1991;11947-11954.
73. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
74. De Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
75. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D.C., Armellino D., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187:1992;1579-1586.
76. Quinn T.P., Peters K.G., De Vries C., Ferrara N., Williams L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. USA. 90:1993;7533-7537.
77. Kaipainen A., Korhonen J., Pajusola K., Aprelikova O., Persico M.G., Terman B.I., Alitalo K. The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J. Exp. Med. 178:1993;2077-2088.
78. Shen H., Clauss M., Ryan J., Schmidt A.M., Tijburg P., Borden L., Connolly D., Stern D., Kao J. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood. 81:1993;2767-2773.
79. H. Gitay-Goren, R. Halaban, Neufeld, Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors, Biochem. Biophys. Res. Commun. 190 (1993) 702-709.
80. Liu B., Earl H.M., Baban D., Shoaibi M.A., Fabra A., Kerr D.J., Seymour L.W. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem. Biophys. Res. Commun. 217:1995;721-727.
81. Ijima K., Yoshikawa N., Connolly D.T., Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 44:1993;959-966.
82. Freeman M.R., Schneck F.X., Gagnon M.L., Corless C., Soker S., Niknejad K., Peoples G.E., Klagsbrun M. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor; A poential role for T cells in angiogenesis. Cancer Res. 55:1995;4140-4145.
83. Baban D.F., Murray J.A., Earl H.M., Kerr D.J., Seymour L.W. Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukaemia. Int. J. Oncol. 8:1996;29-34.
84. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848.
85. Plate K.H., Breier G., Millauer B., Ullrich A., Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumour angiogenesis. Cancer Res. 53:1993;5822-5827.
86. Unemori E., Ferrara N., Bayer E.A., Amento E.P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell Physiol. 153:1992;557-562.
87. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212.
88. Pepper M.S., Ferrara N., Orci L., Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor 1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181:1991;902.
89. Seymour L.W., Shoaibi M.A., Martin A., Ahmed A., Elvin P., Kerr D.J., Wakelam M.J.O. Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells. Lab. Invest. 75:1996;1-11.
90. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and flt 1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:1994;26988-26995.
91. 2+ and von Willebrand factor release in human endothelial cells. Am. J. Pathol. 138:1991;213-221.
92. Berridge M.J., Irvine R.F. Inositol phosphates and cell signalling. Nature. 341:1989;197-200.
93. Guo D., Jia Q., Song H.Y., Warren R., Donner D.B. Vacuolar endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contains SH2 domains. J. Biol. Chem. 270:1995;6729-6733.
94. Majno G., Palade G.E. Studies on inflammation. I. The effect of histamine and serotonin on vascular permeability: An electron microscopic study. J. Biophys. Biochem. Cytol. 11:1961;571-605.
95. Majno G., Shea S.M., Leventhal M. Endothelial contraction induced by histamine-type mediators: An electron microscopic study. J. Cell Biol. 42:1969;647-672.
96. Joris I., Guenoud H.F., Doern G.V., Underwood J.M., Majno G. Capillary leakage in inflammation. A study by vascular labeling. Am. J. Pathol. 137:1990;1353-1363.
97. Hulstrom D., Svensj O. Intravital and electron microscopic study of bradykinin-induced vascular permeability changes using FITC-dextran as a tracer. J. Pathol. 129:1979;125-133.
98. Kohn S., Nagy J.A., Dvorak H.F., Dvorak A.M. Pathways of macromolecular tracer transport across venules and small veins. Lab. Invest. 67:1992;596-607.
99. Feng D., Nagy J.A., Hipp J., Dvorak H.F., Dvorak A.M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine and serotonin. J. Exp. Med. 183:1996;1981-1986.
100. Dvorak A.M., Kohn S., Morgan E.S., Fox P., Nagy J.A., Dvoroak H.F. The vesiculo-vacuolar organelle (VVO). A distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J. Leukocyte Biol. 59:1996;100-115.
101. Simionescu N. Cellular aspects of transcapillary exchange. Physiol. Rev. 63:1983;1536-1579.
102. G.E. Palade, The microvascular endothelium revisited, in: N. Simionescu, M. Simionescu (Eds.), Endothelial Cell Biology in Health and Disease, Plenum Press, New York, 1988, pp. 3-22.
103. Steyger P.S., Baban D.F., Brereton M., Ulbrich K., Seymour L.W. A microscopic examination of the accumulation and distribution of exogenous macromolecules in solid tumours. J. Control. Release. 39:1996;35-46.
104. Roberts W.G., Hasan T. Tumour-secreted vascular permeability factor/vascular endothelial growth factor influence photosensitizer uptake. Cancer Res. 53:1993;153-157.
105. Zhung H.T., Craft P., Scott P.A.E., Ziche M., Weich H.A., Harris A.L., Bicknell R. Enhancement of tumour growth and vascular density by transfection of vascular endothelial cell growth factor into MCF7 human breast carcinoma cells. J. Natl. Cancer Inst. 87:1995;213-219.
106. Claffey K.P., Brown L.F., del Aguila L.F., Tognazzi K., Yeo K.T., Manseau E.J., Dvorak H.F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumour growth, angiogenesis and experimental metastasis. Cancer Res. 56:1996;172-181.
107. Matsumura Y., Kimura K., Yamamoto J., Maeda H. Involvement of kinin-generating cascade in enhanced vascular permeability in tumour tissue. Jpn. J. Cancer Res. 79:1988;1327-1335.
108. Maeda H., Naguchi Y., Sato K., Akaike T. Enhanced vascular permeability in solid tumour is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85:1994;331-334.
109. Ku D.J., Zaleski J.K., Liu S., Brock T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. 265:1993;H586-H592.
110. Collins P.D., Connolly D.T., Williams T.J. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br. J. Pharmacol. 109:1993;195-199.
111. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Steyger P., Ulbrich K., Strohalm J., Duncan R. Influence of molecular size on passive tumour accumulation of soluble macromolecular drug carriers. Eur. J. Cancer. 31:1995;766-770.
112. Brogi E., Schatteman G., Wu T., Kim E.A., Varticovski L., Keyt B., Isner J.M. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J. Clin. Invest. 97:1996;469-476.
113. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
114. Kondo S., Asano M., Suzuki H. Significance of vascular endothelial growth factor/vacular permeability factor for solid tumour growth and its inhibition by the antibody. Biochem. Biophys. Res. Commun. 194:1993;1234-1241.
115. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Gliobastoma growth inhibited in vivo by a dominant negative flt-1 mutant. Nature. 367:1994;576-579.
116. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature. 376:1995;62-66.
117. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:1995;66-70.
118. Carmeliet P., Ferreirs V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439.
119. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
120. Pai J.K., Frank E.A., Blood C., Chu M. Novel ketoepoxides block phospholipase D activation and tumour cell invasion. Anti-Cancer Drug Des. 9:1994;363-372.